See more : Duroc AB (publ) (DURC-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Bright Minds Biosciences Inc. (DRUG.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bright Minds Biosciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Eagle Plains Resources Ltd. (EGPLF) Income Statement Analysis – Financial Results
- Penske Automotive Group, Inc. (PAG) Income Statement Analysis – Financial Results
- Osisko Gold Royalties Ltd (OR) Income Statement Analysis – Financial Results
- Rover Metals Corp. (ROVR.V) Income Statement Analysis – Financial Results
- Medtronic plc (MDT) Income Statement Analysis – Financial Results
Bright Minds Biosciences Inc. (DRUG.CN)
About Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 72.45K | 6.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -72.45K | -6.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.00M | 12.18M | 6.31M | 354.85K | 42.01K |
| General & Administrative | 2.08M | 2.00M | 1.44M | 104.89K | 110.12K |
| Selling & Marketing | 119.42K | 551.86K | 852.15K | 9.62K | 36.60K |
| SG&A | 2.29M | 2.55M | 2.29M | 114.51K | 36.71K |
| Other Expenses | 0.00 | -243.08K | -181.74K | -5.45K | 0.00 |
| Operating Expenses | 7.29M | 14.73M | 8.60M | 469.36K | 78.72K |
| Cost & Expenses | 7.37M | 14.73M | 8.60M | 469.36K | 78.72K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 19.75K | 222.78K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 72.45K | 6.04K | 8.62M | 474.93K | 236.15K |
| EBITDA | -7.28M | -14.96M | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.37M | -14.74M | -8.76M | -469.36K | -78.72K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.56K | -232.93K | -27.64K | -5.45K | 157.43K |
| Income Before Tax | -7.37M | -14.96M | -8.65M | -480.38K | -78.72K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 222.78K | -135.43K | 5.57K | -236.15 |
| Net Income | -7.37M | -15.19M | -8.52M | -485.95K | -78.72K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.98 | -6.15 | -4.74 | -0.38 | -0.06 |
| EPS Diluted | -1.98 | -6.15 | -4.74 | -0.38 | -0.06 |
| Weighted Avg Shares Out | 3.72M | 2.47M | 1.79M | 1.28M | 1.28M |
| Weighted Avg Shares Out (Dil) | 3.72M | 2.47M | 1.79M | 1.28M | 1.28M |
Source: https://incomestatements.info
Category: Stock Reports